← Back to the timeline

Timeline › Pandemic, inflation & war

FDA approves Wegovy for obesity: the GLP-1 boom begins

4 June 2021 · Global (origin DNK) · Global level

Draft: not yet verifiedScience, invention & breakthrough technologyDemographics & society

Why it matters

Novo Nordisk becomes Europe's most valuable company (2023); Eli Lilly reaches a $1tn market value (Nov 2025); food, alcohol and medtech stocks hit

Dalio lens
Bubble seed: new-era technology
Era
Pandemic, inflation & war (2020–)
Track
Technology & science
Asset classes
Equities
Verify via
FDA
Wikipedia
Semaglutide (broader article)
Date check
broader article, not compared

Open in the interactive timeline, with its macro chartsSuggest a correction

Sources

References cited in the Wikipedia article, official and academic ones first.

Previous and next events on the Technology & science track.

Cite this event

Wang, Y. (2026). FDA approves Wegovy for obesity: the GLP-1 boom begins (4 June 2021). In Macro-financial history, 1900–2026, event E0455. https://macrofinancialhistory.com/event/e0455/

@misc{mefh_e0455,
  author = {Wang, Yuhui},
  title = {FDA approves Wegovy for obesity: the GLP-1 boom begins},
  howpublished = {Macro-financial history, 1900–2026, event E0455},
  year = {2026},
  url = {https://macrofinancialhistory.com/event/e0455/}
}